Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial)
Public ClinicalTrials.gov record NCT02660866. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 4, randomized clinical trial to evaluate whether addition of Vorapaxar 2.08 mg daily vs. placebo daily on background antiplatelet therapy, prescribed for 6 months to patients with established peripheral artery disease (PAD) and Intermittent Claudication (IC) treated with standard medical therapy (SMT) would lead to an improvement in the peak walking time (PWT).
Study identification
- NCT ID
- NCT02660866
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 200 participants
Conditions and interventions
Conditions
Interventions
Drug
Eligibility (public fields only)
- Age range
- 40 Years to 90 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2016
- Primary completion
- Jun 30, 2019
- Completion
- Jun 30, 2019
- Last update posted
- May 28, 2018
2016 – 2019
United States locations
- U.S. sites
- 12
- U.S. states
- 10
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Southern Arizona VA Health Care System | Tucson | Arizona | 85723 | Recruiting |
| San Diego VA Medical center | San Diego | California | 92161 | Recruiting |
| VA Eastern Colorado Healthcare System | Denver | Colorado | 80220 | Recruiting |
| Atlanta Heart Specialists | Atlanta | Georgia | 30084 | Recruiting |
| Minneapolis Heart Institute Foundation | Minneapolis | Minnesota | 55407 | Recruiting |
| Minneapolis VA Medical center | Minneapolis | Minnesota | 55417 | Recruiting |
| Creighton University | Omaha | Nebraska | 68131 | Recruiting |
| Northwell Health | Manhasset | New York | 11030 | Recruiting |
| OKlahoma VA Medical Center | Oklahoma City | Oklahoma | 73104 | Recruiting |
| VA Portland Health Care System | Portland | Oregon | 97239 | Recruiting |
| VA North Texas Health Care System | Dallas | Texas | 75216 | Recruiting |
| Texas Tech University Health Science Center | Lubbock | Texas | 79430 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02660866, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 28, 2018 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02660866 live on ClinicalTrials.gov.